Annexon Biosciences, Inc. ( ($ANNX) ) has released its Q4 earnings. Here is a breakdown of the information Annexon Biosciences, Inc. presented to ...
Fintel reports that on March 3, 2025, HC Wainwright & Co. initiated coverage of TuHURA Biosciences (NasdaqCM:HURA) with a Buy ...
Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, Ratings reports. One investment ...
Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report)’s stock price gapped down before the market opened on Monday after Barclays lowered their price target on the stock from $63.00 to $57.00. The ...
Gorgas, President and CEO of Artelo Biosciences. “Notably, enrollment in our Phase 1 study of ART26.12, a Fatty Acid Binding Protein (FABP) inhibitor, has progressed rapidly and is expected to ...
Solid Biosciences reported recent positive data in developing their gene therapy candidate SGT-003. The phase 1/2 INSPIRE ...
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates. Overall, the quarter showcased strong ...
We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...
Cytek will host a conference call to discuss its fourth quarter and year end 2024 financial results on Thursday, February 27, 2024, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the ...
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2024-financial-results ...
Before you invest in Twist Bioscience Corporation (TWST), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.